Myeloproliferative Neoplasms A Contemporary Review

被引:258
作者
Tefferi, Ayalew [1 ]
Pardanani, Animesh [1 ]
机构
[1] Mayo Clin, Div Hematol, Dept Med, 200 First St SW, Rochester, MN 55905 USA
关键词
PRIMARY PROLIFERATIVE POLYCYTHEMIA; DEFINED ESSENTIAL THROMBOCYTHEMIA; RISK ESSENTIAL THROMBOCYTHEMIA; INTERFERON-ALPHA THERAPY; PRIMARY MYELOFIBROSIS; CLONAL HEMATOPOIESIS; AVAILABLE THERAPY; ALLELE BURDEN; WORKING GROUP; VERA;
D O I
10.1001/jamaoncol.2015.89
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) constitute the BCR-ABL1-negative myeloproliferative neoplasms and are characterized by mutually exclusive Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; respective frequencies of these mutations are approximately 95%, 0%, and0% in PV, 60%, 20%, and 3% in ET, and 60%, 25%, and 7% in PMF. These mutations might be accompanied by other mutations that are less specific to myeloproliferative neoplasms but are prognostically relevant, such as additional sex combs-like 1 (ASXL1). Characteristic bone marrow morphology is required for World Health Organization-compliant diagnosis, especially in distinguishing ET from prefibrotic PMF and masked PV. Survival is the longest in ET, although still inferior to that of the age-and sex-matched control population; median survivals for patients younger than 60 years are approximately 33 years for ET, 24 for PV, and 15 for PMF. Major disease complications include thrombosis and leukemic or fibrotic transformation. In PV and ET, risk factors for survival include older age, leukocytosis, and thrombosis, whereas JAK2 mutation in ET is associated with increased risk of thrombosis. In PMF, type 1 or type 1-like CALR mutations are associated with superior and ASXL1 with inferior survival. Prevention of thrombosis in PV is secured by phlebotomy (hematocrit target <45%) and in both PV and ET by low-dose aspirin therapy; high-risk patients derive additional antithrombotic benefit from cytoreductive therapy with hydroxyurea as first-line and interferon-alfa and busulfan as second-line drugs of choice. Although the JAK inhibitor ruxolitinib was recently approved for use in hydroxyurea-resistant PV, its role in routine clinical practice remains debatable. In myelofibrosis, stem cell transplant is the current treatment of choice for genetically or clinically high-risk disease; for all other patients requiring treatment, participation in clinical trials may be preferred because currently available drugs, including JAK inhibitors, are palliative and not shown to be disease modifying.
引用
收藏
页码:97 / 105
页数:9
相关论文
共 76 条
[11]   Presence of calreticulin mutations in JAK2-negative polycythemia vera [J].
Broseus, Julien ;
Park, Ji-Hye ;
Carillo, Serge ;
Hermouet, Sylvie ;
Girodon, Francois .
BLOOD, 2014, 124 (26) :3964-3966
[12]  
BUDDE U, 1984, BLOOD, V64, P981
[13]  
Buhr T, 2012, HAEMATOL-HEMATOL J, V97, P360, DOI 10.3324/haematol.2011.047811
[14]   Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients [J].
Carobbio, Alessandra ;
Thiele, Juergen ;
Passamonti, Francesco ;
Rumi, Elisa ;
Ruggeri, Marco ;
Rodeghiero, Francesco ;
Randi, Maria Luigia ;
Bertozzi, Irene ;
Vannucchi, Alessandro M. ;
Antonioli, Elisabetta ;
Gisslinger, Heinz ;
Buxhofer-Ausch, Veronika ;
Finazzi, Guido ;
Gangat, Naseema ;
Tefferi, Ayalew ;
Barbui, Tiziano .
BLOOD, 2011, 117 (22) :5857-5859
[15]   Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia [J].
Cassinat, Bruno ;
Verger, Emmanuelle ;
Kiladjian, Jean-Jacques .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (02) :188-189
[16]   Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis [J].
Cervantes, Francisco ;
Vannucchi, Alessandro M. ;
Kiladjian, Jean-Jacques ;
Al-Ali, Haifa Kathrin ;
Sirulnik, Andres ;
Stalbovskaya, Viktoriya ;
McQuitty, Mari ;
Hunter, Deborah S. ;
Levy, Richard S. ;
Passamonti, Francesco ;
Barbui, Tiziano ;
Barosi, Giovanni ;
Harrison, Claire N. ;
Knoops, Laurent ;
Gisslinger, Heinz .
BLOOD, 2013, 122 (25) :4047-4053
[17]   Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms [J].
Chen, Edwin ;
Schneider, Rebekka K. ;
Breyfogle, Lawrence J. ;
Rosen, Emily A. ;
Poveromo, Luke ;
Elf, Shannon ;
Ko, Amy ;
Brumme, Kristina ;
Levine, Ross ;
Ebert, Benjamin L. ;
Mullally, Ann .
BLOOD, 2015, 125 (02) :327-335
[18]   HYDROXYUREA FOR PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND A HIGH-RISK OF THROMBOSIS [J].
CORTELAZZO, S ;
FINAZZI, G ;
RUGGERI, M ;
VESTRI, O ;
GALLI, M ;
RODEGHIERO, F ;
BARBUI, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (17) :1132-1136
[19]   TREATMENT OF PRIMARY PROLIFERATIVE POLYCYTHEMIA BY VENESECTION AND BUSULFAN [J].
DEMILIO, A ;
BATTISTA, R ;
DINI, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1987, 65 (01) :121-122
[20]   Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia [J].
Finazzi, Guido ;
Carobbio, Alessandra ;
Guglielmelli, Paola ;
Cavalloni, Chiara ;
Salmoiraghi, Silvia ;
Vannucchi, Alessandro M. ;
Cazzola, Mario ;
Passamonti, Francesco ;
Rambaldi, Alessandro ;
Barbui, Tiziano .
BLOOD, 2014, 124 (16) :2611-2612